Anecova

Benefits

Direct benefits

The fertilization and the very first stages of development of the embryos take place in the same physiological environment that they experience throughout their stay in the uterine cavity. This consists of two elements:
  • The immediate liquid environment containing the nutrients, ions, growth factors, hormones and the like that are only approximated in a static manner by the culture media available in the embryology lab
  • The interaction with the mother’s organism that responds to the presence of the embryo and vice-versa
In addition, studies undertaken so far have received a very positive reaction from patients, and show enthusiasm for taking an active part in the first phases of the development of life.
 

Clinical benefits

The potential clinical benefits of the Anecova approach are numerous and preliminary results are promising. Clinical studies to confirm these results are currently underway.

Potential benefits

Restoring fertilization and early development to the physiological environment may develop better quality embryos both on a morphological and a genetic level.

Despite of the number of existing technologies, since the first IVF realisation in 1978, the technique has been tremendously improved but the yield remains low with ca. 20% to 30% success. To explain this, the literature traditionally refers to the complexity of the system due to the interconnection of relatively numerous parameters that cannot be easily optimized.

Anecova’s solution is expected to open new perspectives in the related domain of ART by reducing the risk inherent to In Vitro embryo's culture (either IVF or ICSI).

It is also expected to surpass GIFT and ZIFT since the use of cell encapsulation allows control of the culture duration and also the convenient retrieval of embryos for possible diagnosis prior to implanting them within the uterine endometrial wall.